Data protection Impressum

Oncology

iOnctura has secured EUR 80 million in a Series B funding round to advance innovative cancer therapies, with a focus on neglected cancers such as uveal melanoma.

iOnctura secures EUR 80 million Series B financing to advance cancer treatments

25 June 2024

Top Stories Western Switzerland

Top Stories from Western Switzerland (May 2024)

28 May 2024

HeroSupport and Calico Biosystems join Tech4Eva, a six-month equity-free accelerator dedicated to advancing women’s health technologies globally.

HeroSupport and Calico Biosystems selected for the Tech4Eva accelerator program

15 May 2024

EP Equity Investment (EPEI), a company dedicated to investing in promising European companies, has acquired a 24.99% stake in Nanobacterie to advance the development of innovative treatments for prostate cancer.

Nanobacterie secures strategic investment from EP Equity to advance prostate cancer treatment

6 May 2024

Researchers at the EPFL have engineered lab-grown mini-colons that replicate the development of colorectal tumors with high fidelity.

EPFL scientists create lab-grown mini-colons to advance colorectal cancer research

29 April 2024

Top Stories Western Switzerland

Business environment

Top Stories from Western Switzerland (March 2024)

26 March 2024

SmellRS is developing an ambitious and innovative technology for the early detection of Alzheimer's disease and the restoration of the sense of smell.

FONGIT Innovation Fund backs HeroSupport and SmellRS to advance healthcare innovation

4 March 2024

Onward Therapeutics’ move marks a critical transition for the company into the clinical stage, solidifying its role in developing innovative cancer treatments.

Onward Therapeutics enters clinical phase with innovative cancer immunotherapy

30 January 2024

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers.

Cellestia Biotech receives CHF 2 million for its pioneering GvHD prevention therapy

23 January 2024

Novochizol technology quantitatively transforms single linear chitosan molecules into cross-linked, uniformly sized nanospheres.

EPFL and Novochizol to collaborate on designing more efficient immunotherapies

2 November 2023

1 2 3 4 5 6 7 … 9